ARQT vs MMC · rev $235.3M vs P/E 22, rev $24.46B
Arcutis Biotherapeutics Inc (ARQT) versus Marsh & McLennan Companies Inc (MMC) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
ARQT currently screens at market cap $1.64B. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Not investment advice. Open the ARQT and MMC stock pages for the full models.
Not investment advice.